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Cromolyn Reduces Levels of the 
Alzheimer’s Disease-Associated 
Amyloid β-Protein by Promoting 
Microglial Phagocytosis
Can Zhang1, Ana Griciuc1, Eloise Hudry2, Yu Wan1, Luisa Quinti1, Joseph Ward1, Angela M. 
Forte1, Xunuo Shen, ChongZhao Ran  3, David R. Elmaleh3 & Rudolph E. Tanzi1
Amyloid-beta protein (Aβ) deposition is a pathological hallmark of Alzheimer’s disease (AD). Aβ 
deposition triggers both pro-neuroinflammatory microglial activation and neurofibrillary tangle 
formation. Cromolyn sodium is an asthma therapeutic agent previously shown to reduce Aβ levels in 
transgenic AD mouse brains after one-week of treatment. Here, we further explored these effects as 
well as the mechanism of action of cromolyn, alone, and in combination with ibuprofen in APPSwedish-
expressing Tg2576 mice. Mice were treated for 3 months starting at 5 months of age, when the earliest 
stages of β-amyloid deposition begin. Cromolyn, alone, or in combination with ibuprofen, almost 
completely abolished longer insoluble Aβ species, i.e. Aβ40 and Aβ42, but increased insoluble Aβ38 
levels. In addition to its anti-aggregation effects on Aβ, cromolyn, alone, or plus ibuprofen, but not 
ibuprofen alone, increased microglial recruitment to, and phagocytosis of β-amyloid deposits in AD 
mice. Cromolyn also promoted Aβ42 uptake in microglial cell-based assays. Collectively, our data reveal 
robust effects of cromolyn, alone, or in combination with ibuprofen, in reducing aggregation-prone Aβ 
levels and inducing a neuroprotective microglial activation state favoring Aβ phagocytosis versus a pro-
neuroinflammatory state. These findings support the use of cromolyn, alone, or with ibuprofen, as a 
potential AD therapeutic.
Alzheimer’s disease (AD) is an insidious neurodegenerative disorder and the major cause of dementia in the 
elderly, with no effective disease-modifying therapy currently available1. Genetic, biochemical, molecular bio-
logical, and pathological evidence supports the amyloid hypothesis, positing that the excessive accumulation of 
Aβ is the primary pathological event leading to neurofibrillary tangles (NFT), neurodegeneration, and neuroin-
flammation in AD2–4. Aβ42 and Aβ40 are the two primary Aβ species, with Aβ42 the more prevalent isoform 
in β-amyloid plaques3–5. Aβ is deposited early in the disease process decades prior to symptoms, suggesting the 
need for secondary prevention of AD in therapies aimed at β-amyloid2. In contrast, neuroinflammation occurs 
throughout the course of the disease, particularly in later stages. Decreasing Aβ42 and NFT levels, and reducing 
neuroinflammation are all considered potentially effective means for preventing and treating AD.
Cromolyn is a small molecule approved for the treatment of asthma. Cromolyn has structural similarity to 
fisetin, an anti-Aβ aggregation molecule, and has been previously shown to significantly inhibit Aβ aggregation 
in vitro6. Additionally, in the transgenic APPswe/PS1ΔE9 mouse model, expressing the familial amyloid pre-
cursor protein (APP) Swedish mutation and the presenilin (PS1) mutation that lacks the exon 9, intraperitoneal 
injection of cromolyn administrated for a week, previously led to a significant and robust (>50%) reduction in 
soluble and insoluble Aβ levels6. Aβ-mediated neurodegeneration and NFT formation both contribute to micro-
glial cell-mediated neuroinflammatory responses in the AD brain7,8. Depending on activation state, microglia 
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can either phagocytose Aβ and display an anti-inflammatory phenotype or secrete pro-inflammatory cytokines 
and free radicals causing neuroinflammation9,10. Previous studies suggest that microglia transition from a largely 
anti-inflammatory/pro-phagocytic to a pro-inflammatory/neurotoxic activation state during AD progression11. 
Pro-inflammatory cytokines produced in response to Aβ accumulation downregulate genes involved in Aβ clear-
ance and promote Aβ plaque deposition, thereby contributing to neurodegeneration. Neuroinflammation can 
also promote vascular leakage through the blood-brain barrier12 and promote the additional generation of Aβ and 
NFT13,14. Thus, neuroinflammation, in combination with Aβ-mediated tauopathy and neurodegeneration, leads 
to a vicious cycle resulting in progressive neuronal cell death, synapse loss, and, ultimately, dementia. Therefore, 
compounds that induce microglial cells into a pro-phagocytic activation state could make useful AD therapeutics.
Here, we investigated whether chronic treatment with cromolyn, alone, or in combination with ibuprofen 
(a non-steroidal anti-inflammatory drug and cox1/cox2 non-specific modulator) affects the levels of Aβ in a 
well-characterized transgenic AD mouse model, the APPswe Tg257615,16. Five month old Tg2576 mice were 
treated with cromolyn, alone, or in combination with ibuprofen via intraperitoneal injection for 3 months, an 
age at which major plaque accumulation is not yet observed. We found that cromolyn, alone, and in combina-
tion with ibuprofen, almost completely abolished the levels of brain TBS-insoluble (formic acid extracted) Aβ, 
which drives deposition of β-amyloid. We also showed that cromolyn (alone and in combination with ibuprofen) 
increased the number of Iba-1 positive microglia surrounding β-amyloid plaques as compared to vehicle-treated 
animals. Finally, we also employed a microglial cell culture model to show that cromolyn (alone and with ibupro-
fen) promoted a microglial activation state defined by enhanced phagocytosis of Aβ42. Collectively, these find-
ings strongly support the potential use of cromolyn and cromolyn plus ibuprofen as therapeutics for AD-related 
β-amyloid deposition and in modulating microglial activation state in a direction toward phagocytosis and, there-
fore, away from neuroinflammation.
Results
We carried out animal studies using the well-characterized APPSwedish-expressing Tg2576 mice. 3-month old 
Tg2576 mice were acclimatized for 2 months and then randomly assigned to a total of 7 treatment groups, 
including 6 drug-treatment groups and one vehicle-treatment group (Table 1). Each group received one dose 
of cromolyn (1.0 or 3.15 mg/kg), ibuprofen (0.5 or 2.0 mg/kg), cromolyn plus ibuprofen (n = 8–10/group), or 
PBS (vehicle; n = 10). The drugs were prepared in sterile PBS and administered by IP, based on 0.1 mL/30 g body 
weight. The treatments were performed 3 times per week for 12 weeks in total. The body weight was measured 2 
weeks after the initial treatment and once per week afterwards. We found that all treatments were well tolerated, 
and there were no significant differences in body weight among the groups throughout the treatment period 
(Supplementary Figure 1). All treated mice were sacrificed at 8-month old and tissues were harvested and pro-
cessed for post-mortem analysis.
Effects of Cromolyn and Ibuprofen on Aβ levels in Tg2576 Mice. We first investigated whether 
cromolyn, ibuprofen, or cromolyn plus ibuprofen influenced brain Aβ levels in the TBS-insoluble (formic acid 
extracted) protein fraction. In the TBS-insoluble fraction, both low and high-dose cromolyn almost completely 
abolished both Aβ40 and Aβ42 species (p < 0.001; vs. vehicle; Fig. 1A; Supplementary Figure 2A), while robustly 
increasing Aβ38 levels. Specifically, low-dose cromolyn decreased Aβ40 and Aβ42 levels by 92.4% (p < 0.001) and 
94.8% (p < 0.001), respectively, and increased Aβ38 levels by 402.0% (p < 0.05) compared to vehicle. High-dose 
cromolyn decreased Aβ40 and Aβ42 levels by 98.7% (p < 0.001) and 99.6% (p < 0.001), respectively, and 
increased Aβ38 levels by 191.6% as compared to vehicle. We also found that low and high-dose ibuprofen alone 
decreased both Aβ40 and Aβ42 levels (p < 0.001 and p < 0.05, respectively; Fig. 1A; Supplementary Figure 2A), 
while robustly increasing Aβ38 levels (p < 0.001 for the high-dose). Combined low-dose cromolyn and ibuprofen 
also led to a significant decrease in Aβ40 and Aβ42 levels (p < 0.001 and p < 0.05, respectively; vs. vehicle; Fig. 1A; 
Supplementary Figure 2A) and a marked increase in Aβ38 levels (p < 0.05; vs. vehicle; Fig. 1A; Supplementary 
Figure 2A). Finally, combined high-dose cromolyn and ibuprofen displayed a significant decrease in both Aβ40 
Group (n) Treatments Dose (mg/kg) Schedule Duration
1 (10) Vehicle PBS 3 X /week; ip 12 weeks
2 (9) Cromolyn (low-dose) 1 3 X /week; ip 12 weeks
3 (8) Cromolyn (high-dose) 3.15 3 X /week; ip 12 weeks
4 (10) Ibuprofen (low-dose) 0.5 3 X /week; ip 12 weeks
5 (10) Ibuprofen (high-dose) 2 3 X /week; ip 12 weeks
6 (10) Combined low-dose (Cromolyn + Ibuprofen) 1 + 0.5 (respectively) 3 X /week; ip 12 weeks
7 (9) Combined high-dose (Cromolyn + Ibuprofen)
3.15 + 2 
(respectively) 3 X /week; ip 12 weeks
Table 1. Experimental groups and treatments. Three-month old Tg2576 mice were randomly assigned to 7 
treatment groups and then acclimatized for 2 months at the study facility, followed by vehicle or drug treatment. 
The first was control group receiving vehicle (PBS) treatment (n = 10). The drug-treatment groups were divided 
to low and high-dose groups, receiving either ibuprofen, cromolyn or their combination (n = 8–10). All 7-group 
mice were IP injected based on 0.1 mL/30 g body weight for 3 times per week for 12 weeks and were sacrificed at 
8-month old. Tissues were harvested and processed for post-mortem analysis.
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and Aβ42 levels (p < 0.05 and p < 0.001, respectively; vs. vehicle; Fig. 1A), but with no significant change in Aβ38 
levels as compared to vehicle (Fig. 1A; Supplementary Figure 2A).
We next analyzed the effects of cromolyn and ibuprofen, alone, or in combination, on the Aβ42:Aβ40 ratio in 
brain TBS-insoluble fractions as compared to vehicle. Neither cromolyn nor ibuprofen, alone, affected Aβ42:Aβ40 
ratios vs. vehicle (Fig. 1B; Supplementary Figure 2B). Interestingly, combined low-dose cromolyn with ibuprofen 
led to an increased Aβ42:Aβ40 ratio (p < 0.05; vs. vehicle; Fig. 1B; Supplementary Figure 2B). However, this did 
not appear to be dose-dependent since combined high-dose cromolyn with ibuprofen did not significantly affect 
the Aβ42:Aβ40 ratio vs. vehicle (Fig. 1B; Supplementary Figure 2B).
We next investigated the effects of cromolyn and ibuprofen, alone, or in combination on brain TBS-soluble 
protein fractions. Neither cromolyn, nor ibuprofen alone, signicantly affected Aβ levels, although high-dose cro-
molyn increased levels of soluble Aβ42 (by 126.0%; p < 0.05; Fig. 2A; Supplemental Figure 2C), as well as the 
soluble Aβ42:Aβ40 ratios (Fig. 2B; Supplemental Figure 2D). In addition, combined high-dose cromolyn and ibu-
profen significantly increased levels of soluble Aβ40 and Aβ38 levels (p < 0.05; Fig. 2A; Supplemental Figure 2C). 
With regard to effects of cromolyn and ibuprofen, alone, or in combination on Aβ42:Aβ40 ratios in TBS-soluble 
fractions, high-dose cromolyn, alone, significantly increased Aβ42:Aβ40 ratios as compared to vehicle (by 40.0%; 
p < 0.01; Fig. 2B; Supplemental Figure 2D).
We next investigated whether cromolyn and ibuprofen, alone, or in combination, affected Aβ levels in plasma 
(Fig. 3A,B; Supplementary Figure 3A,B) and CSF (Fig. 4A,B; Supplementary Figure 3C,D), as compared to vehi-
cle. Only low-dose cromolyn, alone, increased the plasma Aβ42:Aβ40 ratios (p < 0.05; Fig. 3B; Supplementary 
Figure 3B). However, this effect was not dose-dependent since high-dose cromolyn, alone, did not exhibit similar 
effects.
Overall, we showed that cromolyn and ibuprofen, alone, and/or in combination with each other, decreased 
levels of cerebral TBS-insoluble Aβ40 and Aβ42, and increased soluble brain or plasma Aβ species and Aβ42:Aβ40 
ratios (cromolyn, alone). In summary, these findings are suggestive of an anti-aggregation/pro-clearance mecha-
nism of cromolyn and ibuprofen, alone, or in combination with each other on cerebral Aβ depositon.
Effects of Cromolyn and Ibuprofen on Microglia and Aβ. Acute treatment with cromolyn for one 
week was previously shown to lead to an increased number of microglia around β-amyloid plaques6. We therefore 
performed a stereological analysis to determine if similar effects could be observed after chronic exposure (12 
weeks beginning at 5 months old) with cromolyn and ibuprofen, alone, or in combination with each other. Brains 
in the vehicle group displayed minimal β-amyloid burden, consistent with previous reports in the Tg2576 mouse 
model at this age, and no significant changes in the β-amyloid plaque density (Supplementary Figure 4A) or 
β-amyloid load (Supplementary Figure 4B) were observed across the treatment groups. These findings are likely 
explained by the fact that 8 month old Tg2576 mice exhibit minimal plaque pathology.
Figure 1. Cromolyn and/or ibuprofen robustly affected Aβ levels and Aβ42:Aβ40 ratios in brain TBS-insoluble 
samples. (A,B) MesoScale Aβ-triplex analyses were applied to brain TBS-insoluble samples. Differences in Aβ 
levels (A) and Aβ(42:40) ratios (B) were assessed comparing various treatment groups to vehicle. Mean ± SEM; 
n ≥ 8 (Table 1); *p < 0.05; ***p< 0.001 (vs. vehicle); one-way ANOVA with Dunnett’s multiple comparison test. 
Abbreviations: Aβ(42:40): Aβ42: Aβ40.
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We next assessed the percentage of β-amyloid deposits that overlapped with microglial processes. As shown 
in the representive images of colocalization of β-amyloid deposits (detected by the Bam10 antibody, green) and 
microglia (detected by the Iba1-specific antibody, red) (Fig. 5A), the percentage of β-amyloid deposits occu-
pied by Iba1-positive processes was calculated for each deposit in all animals. Low-dose cromolyn (p < 0.05; vs. 
Figure 2. High dose cromolyn and combined high dose cromolyn with ibuprofen upregulated Aβ levels in 
brain TBS-soluble samples; High dose cromolyn elevated Aβ42:Aβ40 ratios in brain TBS-soluble samples.  
(A,B) MesoScale Aβ-triplex analyses were applied to brain TBS-soluble samples. Differences in Aβ levels 
(A) and Aβ42:Aβ40 ratios (B) were analyzed comparing various treatment groups to vehicle. Mean ± SEM 
(normalized to vehicle); n ≥ 8 (Table 1); *p < 0.05; **p < 0.01 (vs. vehicle); one-way ANOVA with Dunnett’s 
multiple comparison test.
Figure 3. Low dose cromolyn increased plasma Aβ42:Aβ40 ratios. (A,B). MesoScale Aβ-triplex analyses were 
applied to plasma samples. Differences in Aβ levels (A) and Aβ42:Aβ40 ratios (B) in plasma were analyzed 
comparing various treatment groups to vehicle. Mean ± SEM; n ≥ 8 (Table 1); *p < 0.05 (vs. vehicle), one-way 
ANOVA with Dunnett’s multiple comparison test.
www.nature.com/scientificreports/
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vehicle; Fig. 5B) increased the overlap of microglial processes with β-amyloid deposits, while high dose cromolyn 
exhibited only a trend in this direction. No changes in overlap were observed after treatment with the low or 
high doses of ibuprofen (Fig. 5B). Combined low-dose and high-dose cromolyn with ibuprofen also significantly 
increased the overlap of β-amyloid deposits with microglial processes as compared to ibuprofen alone (p < 0.01; 
Fig. 5B). Overall, our results in the 12-week treatment period were consistent with the previous acute 7-day study 
suggesting that microglial recruitment and subsequent clearance of Aβ is increased by cromolyn. Treatment with 
ibuprofen, alone or in association with cromolyn, had no impact on this parameter.
To further explore the effects of cromolyn and ibuprofen, alone, or in combination, we next employed a micro-
glial cell-based assay to assess effects on Aβ42 uptake. Specifically, BV2 murine microglial cell cultures were 
treated with cromolyn and/or ibuprofen (10 μM, 100 μM and 1 mM, respectively) for 16 hours. Subsequently, 
cells were incubated with soluble Aβ42 and the compounds for 3 hours. After incubation, cells were collected for 
ELISA analysis to measure Aβ42 levels. BV2 microglial cells treated with cromolyn, alone (100 μM, 1 mM), and 
with cromolyn plus ibuprofen (100 μM, 1 mM for each compound), exhibited increased Aβ42 uptake relative to 
cells treated with vehicle (n = 3; p < 0.001 and p < 0.01, respectively, one-way ANOVA with Tukey’s test; Fig. 5C). 
In contrast, BV2 microglial cells treated with ibuprofen (10 μM, 100 μM, 1 mM), alone, displayed no change in 
Aβ42 uptake levels relative to cells treated with vehicle. Collectively, the microglial cell-based studies were con-
sistent with the results of the Tg2576 mouse-based studies. Moreover, the Tg2576 mouse and cell-based studies 
support the notion that cromolyn decreased TBS-insoluble Aβ levels at least, partially, by promoting a microglial 
pro-phagocytic state that leads to enhanced clearance of Aβ.
Discussion
Excessive accumulation and aggregation of Aβ in senile plaques are key pathological events leading to AD-related 
dementia2–4. Numerous pharmacological approaches to prevent and treat AD have targeted Aβ production, 
accumulation, and/or aggregation, most recently focusing on pre-symptomatic, prodromal, and mildly affected 
patients17. In addition, the neuroinflammatory response driven by both β-amyloid and neuronal cell death has 
emerged as an important therapeutic target for modifying AD progression, especially for symptomatic AD 
patients. Here, we studied the effects of cromolyn and the NSAID, ibuprofen, alone, and in combination, on AD 
pathogenesis in Tg2576 AD mice and microglial cell clearance assays.
Previously, we showed that cromolyn is a strong anti-Aβ aggregation agent and that 1-week treatment 
decreased Aβ content in AD mice6. Here we tested longer term (12 week) treatment in relatively young Tg2576 
AD mice with minimal amyloid deposition. We treated these animals with cromolyn and ibuprofen, alone or in 
combination with each other, via IP injection starting at five months old, for a total of three months. We showed 
that cromolyn and ibuprofen, alone or in combination with each other, almost abolished longer Aβ peptides (i.e. 
Aβ40 and Aβ42), while increasing the shorter Aβ38 peptide in brain TBS-insoluble fractions, which serve as the 
major source of plaque amyloid. (Fig. 1; Supplmental Figure 2). In contrast, we observed increases in various 
Aβ species in TBS-soluble samples in Tg2576 mice treated with high-dose cromolyn and combined high-dose 
cromolyn plus ibuprofen (Fig. 2). Equilibrium of soluble and insoluble Aβ plays a critical role in the pathogenesis 
Figure 4. Cromolyn and/or ibuprofen did not significantly influence the levels of Aβ and Aβ42:Aβ40 ratios in 
mouse CSF samples. (A,B) MesoScale Aβ-triplex analyses were applied to CSF samples. Differences in Aβ levels 
(A) and Aβ42:Aβ40 ratios (B) were analyzed comparing various treatment groups to vehicle. Mean ± SEM; n 
≥8 (Table 1); one-way ANOVA with Dunnett’s multiple comparison test.
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of AD and thus offers crucial insights in developing an effective AD therapeutic18,19. Recently we reported that 
cromolyn significantly impacted brain Aβ levels in transgenic APPswe/PS1ΔE9-expressing (also known as APP/
PS1) mice with abundant cerebral β-amyloid plaques6. Our current findings suggest that cromolyn, alone, and 
combined with ibuprofen decreases insoluble Aβ levels and could potentially attenuate β-amyloid deposition, 
while increasing soluble pools of Aβ. Moreover, our results support a molecular mechanism for cromolyn that 
not only decreases cerebral Aβ aggregation but also leads to an up-regulation of plasma Aβ42:Aβ40 ratios perhaps 
owing to increased export of soluble Aβ42 out of the brain (Fig. 3).
While our previous study implicated anti-aggregation effects of cromolyn on Aβ6, they also suggested increased 
recruitment of microglia to amyloid plaques in Tg2576 AD mice. Our current study showed that cromolyn, 
but not ibuprofen, significantly promoted microglial cell reactivity to Aβ deposition. Moreover, in microglial 
cell-based assays, we showed that cromolyn was able to upregulate microglial-uptake of Aβ in a dose-dependent 
manner (Fig. 5). Together, these findings suggest that cromolyn may not only prevent aggregation of Aβ but also 
induce the transition of microglia cells from a pro-inflammatory/neurotoxic to a pro-phagocytic/neuroprotective 
activation state. These findings carry implications for the potential use of cromolyn, alone, or in combination with 
ibuprofen in the treatment of AD. If cromolyn were only affecting aggregation of Aβ it would likely need to be 
used in subjects positive for amyloid deposition prior to symptoms, prodromally, or in very mild, early stage AD 
patients. The observed effects of cromolyn (alone, or in combination with ibuprofen) on recruitment of microglia 
to plaques and enhanced microglial uptake of Aβ, suggest an additional role for cromolyn in the potential ability 
to convert microglial activation state from one favoring neuroinflammation to one promoting phagocytosis of 
Aβ state. The molecular mechanisms by which cromolyn regulates microglial activity in Aβ42 uptake will require 
future studies.
Figure 5. Cromolyn, but not ibuprofen, increased microglial activity in AD mice. (A,B) Cromolyn increased 
microglial activity related to β-amyloid deposits in mice. Iba1-positive microglial processes (red) colocalizing 
with β-amyloid deposits (green) were showed (A) and quantified (B). We represented pictures of β-amyloid 
deposits and Iba-1 positive microglia for the highest concentration only from each drug treatment group. 
Mean ± SEM; *p < 0.05, **p < 0.01, one-way ANOVA with post-hoc Tukey’s multiple comparison test.  
(C) Cromolyn, but not ibuprofen, promoted Aβ42 uptake in BV2 microglial cell culture studies. BV2 microglial 
cell cultures were treated with cromolyn and/or ibuprofen (10 μM, 100 μM, 1 mM) for 16 hours. Afterwards, 
cells were incubated with soluble Aβ42 and the compounds for additional 3 hours. After incubation, cells 
were collected for Aβ ELISA analysis. BV2 microglial cells treated with cromolyn (100 μM, 1 mM), and with 
combined cromolyn and ibuprofen (100 μM, 1 mM for each compound) exhibited increased Aβ42 uptake levels 
relative to BV2 microglia treated with vehicle. Mean ± SEM; n = 3; **p < 0.01, ***p < 0.001, one-way ANOVA 
post-hoc Tukey’s multiple comparison test.
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In summary, AD transgenic mouse model and microgial cell-based studies of cromolyn, alone, or in combina-
tion with ibuprofen, together with the favorable safety profile of these FDA-approved drugs, strongly support their 
potential for effectively treating and preventing AD. Given the effects of these drugs on both β-amyloid deposition 
and microglial activation state, our findings suggest that cromolyn, alone, or in combination with ibuprofen, could 
serve as an effective AD therapeutic in both early and later stage cases of the disease. Cromolyn and ibuprofen 
(ALZT-OP1) are currently in a phase three clinical trial (COGNITE) for the treatment of AD (http://www.alzfo-
rum.org/therapeutics/alzt-op1; https://clinicaltrials.gov/ct2/show/NCT02547818?term=ALZT+OP1&rank=2).
Material and Methods
Animals. Animal housing, handling and procedures were conducted under the protocols and/or guidelines 
approved by the Institutional Animal Care and Use Committee (IACUC) of Cephrim Biosciences, Inc. Male, 
transgenic APPswe mice (Tg line 1349; B6:SJL-Tg2576Kha), aged between 11 to 12 weeks, were purchased from 
Taconic and previously reported15,16. Upon delivery, they were maintained in individual housing. Animals were 
randomly assigned into one of the seven treatment groups and then were given an extra 2 months to grow in the 
facility in order to reach 5 month-old age for treatments. The treatment solutions (Table 1) were prepared by and 
transferred from AZ Therapeutics and stored at 4 °C during the study. All treatments were conducted three times 
a week intraperitoneally (IP) with the injection volume of 3 mL/kg (Table 1). As additional control for AD β-amy-
loid pathology, we also obtained additional young Tg2576 mice and sacrificed 5 days upon delivery (11–12 weeks 
old), followed by tissue harvesting, processing analysis.
Antibodies. The mouse monoclonal Bam10 antibody was utilized to detect β-amyloid plaques through 
immunohistochemistry (Sigma-Aldrich; 1:500). The rabbit polyclonal anti-Iba-1 antibody was used to detect 
microglia (Wako Chemicals; 1:500). The secondary antibodies included the goat anti-mouse Alexa Fluor 488 and 
goat anti-rabbit Alexa Fluor 568-conjugated antibodies (ThermoFisher; 1:1,000). The DAPI-containing mounting 
media was from Dako (Carpinteria, CA).
Tissue harvest and protein extraction. We processed the tissue and performed post-mortem anal-
ysis according to methods previously reported6,20–23. Mice were transcardiacally perfused with ice cold 
phosphate-buffered saline buffer solution (PBS) and the brain was removed. Hemispheres were then weighed and 
homogenized with 5 × volume tris-buffered saline (TBS) buffer solution (mL; based on weight in mg) containing 
1 × Halt protease inhibitor cocktail (Thermo Fisher Scientific) and 5 mM EDTA. This step was utilized to generate 
total TBS extracted brain samples (TTBS), which were then processed by ultracentrifugation at 100,000 g for 1 hr 
at 4 °C. The supernatant was collected as TBS-soluble brain samples (STBS). The pellet was further extracted in 
400 μL of 70% formic acid (FA) followed by homogenization and subsequent ultracentrifugation at 100,000 g for 
1 hr at 4 °C. The supernatant was collected as TBS-insoluble, or also known as FA-soluble samples. Furthermore, 
we processed TTBS by adding 3X volume M-PER (Mammalian Protein Extraction Reagent) (Thermo Fisher 
Scientific) with 1X Halt protease inhibitor cocktail, followed by centrifugation at 10,000 g for 20 minutes at 4 °C. 
The supernatant was transferred to a new Eppendorf tube and collected as total proteins (or MPER-processed 
TBS), which contained membrane proteins, e.g. APP-FL and APP-CTFs. BCA analysis was performed on total 
proteins to determine their concentrations24,25.
MesoScale Aβ analysis. Levels of Aβ peptides were determined using protocols suggested by the manufac-
turer and have been previously reported23,26–29. For this purpose, we utilized an electrochemi-luminescence-based 
multi-array method on the platform of the Quickplex SQ 120 system (by the Meso Scale Diagnostics LLC). The 
6E10 MesoScale Aβ 3-plex kits were utilized to detect the Aβ triplex peptides (i.e. Aβ[40/38/42]) in a 96-well-based 
assay system. Briefly, 96-well plates were blocked with diluents provided by the manufacturer with shaking for 
1 hour at room temperature (RT). Next, the protein samples and the MesoScale protein standards were resus-
pended in the manufacturer-supplied detection antibodies. The mixed solutions were then placed on a shaker for 
2 hours at RT, followed by washing and adding of the reading buffer. Next, the electrochemi-luminescence signals 
were captured by the MesoScale SQ 120 system and robust signals were obtained for all samples and standard 
proteins. Finally, sample Aβ40, Aβ38 and Aβ42 levels were analyzed using the MesoScale protein standards. 
TBS-soluble Aβ levels were further normalized to sample total protein concentrations. For TBS-insoluble samples 
whose Aβ levels were even lower than the lowest protein standard in some treatment groups, imputation values 
were calculated by taking half the minimum value of each group for inclusion.
Immunohistochemistry (IHC). Serial sagittal paraffin embedded sections were cut at 5μm and two sec-
tions were placed on each slide. One of ten set slices were immunostained with a rabbit anti-human Aβ antibody 
(Immuno- Biological Laboratories, 1:500) for amyloid plaques, followed by biotinylated goat anti-rabbit sec-
ondary antibody (Vector Laboratories) and developed using the ABC Elite and DAB kits (Vector Laboratories). 
Images were obtained using an Axioscope A1 microscope (Carl Zeiss) and were analyzed to determine the 
amyloid load using SWIFT M1000-D under the 10 × objective (after background correction to avoid uneven 
lighting). To analyze the colocalization and quantify the overlap between amyloid plaques and microglial cells, 
sagittal sections were blocked in PBS with 10% NGS, and immunostained overnight with a mouse anti-human 
amyloid antibody (Bam10, Sigma-Aldrich, 1:500) for amyloid plaques and a rabbit anti-Iba-1 for microglia 
(Wako Chemicals, 1:500). The next day, the sections were thoroughly washed in PBS, incubated with 1:1000 goat 
anti-mouse Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 568-conjugated antibodies (ThermoFisher) for 2 h 
at room temperature, washed again in PBS, and coverslipped with fluorescent mounting media containing DAPI 
(Dako, Carpinteria, CA). Tile-scan images were collected on a Zeiss Axio Imager Z epifluorescence microscope 
equipped with AxioVision software and modified for automated acquisition of entire cortices, using either 5 × or 
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20 × objectives. Exposure times for each specific immunostaining were maintained unchanged between each slice 
imaged. Quantification of the amyloid load and amyloid density in the cortex was done with ImageJ (NIH) using 
the “Analyze Particles” function after background subtraction and application of a median filter. The percentage 
of amyloid deposits covered by Iba1 positive processes was calculated by applying a threshold to each amyloid 
deposit image, selecting the corresponding region of interest (“plaque”) and applying this “plaque mask” to the 
Iba-1 channel in order to identify the area of amyloid colocalizing with Iba-1 signal.
Aβ uptake assay. BV2 microglial cells were cultured in DMEM containing 10% heat-inactivated fetal 
bovine serum, 2mM L-Glutamine and 1% penicillin/streptomycin (Life Technologies). BV2 cells were treated 
for 16 hours with cromolyn (10 μM, 100 μM, 1 mM) and/or ibuprofen (10 μM, 100 μM, 1 mM). Subsequently, 
cells were incubated with 2 μg/ml Aβ42 (AnaSpec) and the above-mentioned compounds in serum-free DMEM 
medium for 3 hours. Afterwards, cells were extensively washed with PBS and were lysed in RIPA lysis buffer 
(EMD Millipore) supplemented with EDTA-free protease inhibitors (Roche), Halt phosphatase inhibitor cocktail 
(ThermoFisher Scientific) and 2 mM 1,10 phenantroline (Sigma). Lysates were centrifuged at 12,000 g at 4 °C for 
15 minutes and supernatants were collected. Aβ42 levels were measured in the supernatants using Aβ42 ELISA 
kit (Wako Chemicals) and normalized to total protein concentration that was assessed by BCA method (Pierce).
Data analysis. Protein levels from various treatments were compared to the vehicle treatment. Protein levels 
were demonstrated as means ± SEM in each treatment group. P values < 0.05 were considered statistically signif-
icant. One-way ANOVA with Dunnett’s multiple comparison test was used to compared the differences between 
drug-treatment group to vehicle for MSD Aβ studies. One-way ANOVA with Tukey’s test was used to compare 
the difference among multiple treatments for IHC and microglial cell-based studies.
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